Iowa § 144E.6 Provider recourse

Iowa Statutes

§ 144E.6 — Provider recourse

Iowa § 144E.6

Title IVPUBLIC HEALTH

Ch. 144EEXPERIMENTAL TREATMENTS FOR TERMINALLY ILL PERSONS

This text of Iowa § 144E.6 (Provider recourse) is published on Counsel Stack Legal Research, covering Iowa primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Iowa Code § 144E.6 (2026).

Text

1.To the extent consistent with state law, the board of medicine created under chapter §144E.6, EXPERIMENTAL TREATMENTS FOR TERMINALLY ILL PERSONS 4 147 shall not revoke, fail to renew, suspend, or take any action against a physician’s license based solely on the physician’s recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product, or device, or an individualized investigational treatment.

2.To the extent consistent with federal law, an entity responsible for Medicare certification shall not take action against a physician’s Medicare certification based solely on the physician’s recommendation that a patient have access to an investigational drug, biological product, or device, or an individualized investigational treatment.

Free access — add to your briefcase to read the full text and ask questions with AI

1. To the extent consistent with state law, the board of medicine created under chapter
§144E.6, EXPERIMENTAL TREATMENTS FOR TERMINALLY ILL PERSONS 4
147 shall not revoke, fail to renew, suspend, or take any action against a physician’s license
based solely on the physician’s recommendations to an eligible patient regarding access to
or treatment with an investigational drug, biological product, or device, or an individualized
investigational treatment.
2. To the extent consistent with federal law, an entity responsible for Medicare
certification shall not take action against a physician’s Medicare certification based solely
on the physician’s recommendation that a patient have access to an investigational drug,
biological product, or device, or an individualized investigational treatment.